{"gene":"ISG20","run_date":"2026-06-13T19:06:35","timeline":{"discoveries":[{"year":2001,"finding":"ISG20/HEM45 protein functions as a 3' to 5' exonuclease in vitro, displaying a pH optimum of ~7.0, preferring Mn2+ as a metal cofactor, and degrading single-stranded RNA at a rate approximately 35-fold higher than single-stranded DNA.","method":"In vitro biochemical exonuclease assay with purified protein; metal cofactor and pH optimization experiments","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — direct in vitro reconstitution of enzymatic activity with defined substrates, metal cofactor characterization, and quantitative rate comparisons","pmids":["11401564"],"is_preprint":false},{"year":2004,"finding":"Crystal structure of human ISG20 at 1.9 Å resolution reveals it complexed with two Mn2+ ions and UMP; it belongs to the DEDDh group of RNases and its active site is structurally similar to DNases (E. coli DNA Pol III ε subunit and Exo I). Distinctive residues Met14 and Arg53 form hydrogen bonds with the 2'-OH of the UMP ribose, likely conferring RNA substrate preference.","method":"X-ray crystallography at 1.9 Å with Mn2+ and UMP ligands; structural comparison with homologs","journal":"FEBS letters","confidence":"High","confidence_rationale":"Tier 1 / Strong — crystal structure with bound substrate analog and metal cofactors; active site residues identified and compared to mechanistically characterized homologs","pmids":["15527770"],"is_preprint":false},{"year":2000,"finding":"The ISG20 promoter lacks TATA and CAAT elements; basal transcriptional activity depends on Sp-1 and USF-1. A unique ISRE mediates both type I and type II IFN induction strictly dependent on IRF-1, and this ISRE also contributes to constitutive transcriptional activity.","method":"Promoter cloning, deletion analysis, reporter assays, EMSA for Sp-1, USF-1, and IRF-1 binding; dominant-negative and overexpression of transcription factors","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal promoter dissection methods (reporter assays + EMSA + factor manipulation) in a single rigorous study","pmids":["10871365"],"is_preprint":false},{"year":2003,"finding":"ISG20 exerts antiviral activity against RNA genomic viruses (VSV, influenza, EMCV) but not DNA adenovirus; it specifically inhibits VSV mRNA synthesis and protein production. Antiviral effect requires exonuclease activity, as the exonuclease-inactive mutant has no antiviral effect. The inactive mutant can inhibit ISG20 exonuclease activity in vitro (dominant-negative), and its expression reduces IFN-mediated VSV inhibition.","method":"Overexpression of wild-type and exonuclease-inactive ISG20 in HeLa cells; viral infection assays; mRNA and protein synthesis analysis; in vitro exonuclease inhibition by dominant-negative mutant","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — active-site mutagenesis linked to cellular antiviral phenotype; dominant-negative in vitro validation; multiple RNA viruses tested","pmids":["12594219"],"is_preprint":false},{"year":2004,"finding":"ISG20 induction by synthetic dsRNA (poly I:C) is stronger and faster than by IFN. Transcriptional activation of ISG20 by dsRNA involves initial NF-κB (p50/p65) binding to a κB element followed by IRF-1 binding to the ISRE. Contrary to IFN, dsRNA induces nuclear matrix enrichment of ISG20.","method":"Reporter assays; EMSA; chromatin-based binding assays; immunofluorescence/subcellular fractionation","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA and reporter assays in a single lab; two transcription factor pathways identified with orthogonal methods","pmids":["15064705"],"is_preprint":false},{"year":2005,"finding":"ISG20 inhibits HIV-1 replication; antiviral effect requires the exonuclease activity of ISG20, as exonuclease-inactive mutant ISG20 shows no antiviral effect. HIV-1-induced apoptosis is significantly reduced in cells infected with HIV-1 expressing ISG20.","method":"HIV-1-derived virus expressing ISG20 (HIV-1NL4-3ISG20); replication kinetics in CEM cells and PBMCs; exonuclease-inactive mutant comparison","journal":"The Journal of general virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — active-site mutagenesis linked to antiviral phenotype; single lab with clear genetic controls","pmids":["16033969"],"is_preprint":false},{"year":2006,"finding":"Endogenous ISG20 localizes predominantly to the nucleolus (dense fibrillar component, the major site for rRNA processing) and Cajal bodies, in addition to diffuse cytoplasmic and nucleoplasmic distribution. ISG20 is associated with SMN-containing macromolecular nuclear complexes and with U1, U2 snRNAs, and U3 snoRNA. IFN treatment increases ISG20 accumulation in Cajal bodies.","method":"Immunofluorescence, electron microscopy, co-immunoprecipitation of SMN complexes, RNA immunoprecipitation for snRNAs/snoRNAs, coilin-dsRed coexpression","journal":"Journal of cellular biochemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple imaging and biochemical methods in single lab; endogenous protein localization with functional nuclear complex association","pmids":["16514659"],"is_preprint":false},{"year":2010,"finding":"ISG20 inhibits positive-strand RNA viruses including HCV, bovine viral diarrhea virus, hepatitis A virus, and yellow fever virus in a cell-type-specific manner, but not SARS-CoV in Huh7.5 cells. All antiviral effects require exonuclease activity. The closely related paralogs ISG20L1 and ISG20L2 do not inhibit HCV replication.","method":"Ectopic overexpression; exonuclease-inactive mutant comparison; viral replication assays across multiple virus families and cell types","journal":"Virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — active-site mutagenesis confirms mechanistic requirement across multiple viruses; paralog specificity established; single lab","pmids":["21036379"],"is_preprint":false},{"year":2017,"finding":"ISG20 inhibits HBV replication by degrading HBV RNA. The susceptibility element was mapped to the HBV RNA terminal redundant region containing the epsilon (ε) stem-loop. ISG20 binds the ε stem-loop directly in vitro in the absence of other cellular proteins (EMSA), with the lower stem portion of ε being the major binding site. The C-terminal ExoIII domain of ISG20 is responsible for ε binding; deletion of ExoIII abolishes in vitro binding and intracellular HBV RNA degradation. Enzymatic-inactive ISG20D94G retains antiviral activity by preventing pgRNA encapsidation via ISG20-ε interaction even without degradation.","method":"EMSA (direct binding); ExoIII domain deletion; HBV ε structure mutants; ISG20D94G catalytic mutant; encapsidation assays; cellular HBV RNA decay assays","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro direct binding by EMSA, domain deletion mapping, catalytic mutant, structural mutants of RNA target; multiple orthogonal methods in single rigorous study","pmids":["28399146"],"is_preprint":false},{"year":2018,"finding":"ISG20 localizes primarily to Cajal bodies in the nucleus when ectopically expressed. In the context of alphavirus restriction, ISG20 does not directly degrade viral RNAs; instead, it upregulates over 100 other genes including IFIT1, an ISG that suppresses translation of alphavirus RNAs, leading to indirect inhibition of viral RNA translation.","method":"Inducible ectopic expression system; Isg20-/- mice; RNA-seq of ISG20-expressing cells; viral RNA degradation assays (negative finding for direct RNA degradation); IFIT1 protein quantification; alphavirus replication assays in wild-type vs Isg20-/- mice","journal":"mSphere","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO mice + ectopic expression + RNA-seq; direct RNA degradation assay is negative; indirect mechanism supported by multiple approaches in single lab","pmids":["30232164"],"is_preprint":false},{"year":2018,"finding":"ISG20 exhibits potent antibunyaviral activity (Peribunyaviridae, Hantaviridae, Nairoviridae) but phleboviruses largely escape inhibition. Antibunyaviral activity depends on RNase activity. In vitro evolution of resistant BUNV mapped sequence determinants of ISG20 sensitivity/resistance.","method":"ISG-expression flow cytometry screen of ~500 ISGs; minigenome/VLP assay; exonuclease-inactive mutant; in vitro viral evolution for resistance mapping","journal":"Journal of virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional screen validated with mechanistic assays; RNase activity requirement confirmed by mutagenesis; viral resistance determinants mapped","pmids":["29695422"],"is_preprint":false},{"year":2019,"finding":"ISG20 inhibits VSV replication by decreasing viral protein synthesis without degrading viral RNA. ISG20 exerts translational control over non-self RNAs (including those from transfected DNA) while sparing endogenous transcripts. This activity correlates with ISG20's localization in cytoplasmic processing bodies (P-bodies). Murine ISG20 ortholog functions similarly; Isg20-/- mice show increased susceptibility to viral infection.","method":"VSV infection assays; ribosome profiling / translation assays; viral RNA stability assays (negative for degradation); subcellular localization by live imaging to P-bodies; Isg20-/- mouse infection model; non-self RNA transfection controls","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (translation assay, RNA stability, P-body localization, KO mice); self/non-self discrimination established; replicated with murine ortholog","pmids":["31600344"],"is_preprint":false},{"year":2020,"finding":"m6A-modified HBV transcripts are selectively recognized and degraded by ISG20. The m6A reader protein YTHDF2 acts as a cofactor: ISG20 forms a complex with YTHDF2 and m6A-modified HBV RNA (demonstrated using enzymatically inactive ISG20D94G). Silencing of m6A methyltransferases or YTHDF2 reduces ISG20-mediated HBV RNA degradation. m6A at position A1907 within the ε stem-loops is the critical site.","method":"ISG20D94G co-immunoprecipitation of YTHDF2 and m6A RNA; methyltransferase knockdown; YTHDF2 knockdown; HBV m6A site mutants (5', 3', both termini); HBV RNA decay assays","journal":"PLoS pathogens","confidence":"High","confidence_rationale":"Tier 2 / Strong — catalytic mutant trapping of complex, RNA mutants, multiple knockdowns; two orthogonal labs (Siddiqui group + earlier Liu/Guo work); complex mechanistically defined","pmids":["32059034"],"is_preprint":false},{"year":2021,"finding":"ISG20 is required for IFN-induced degradation of HBV cccDNA. ISG20 is the only type I and II IFN-induced nuclear protein with annotated nuclease activity. ISG20 localizes to nucleoli of IFN-stimulated hepatocytes and is enriched on deoxyuridine-containing ssDNA mimicking APOBEC3A-deaminated HBV DNA. Co-expression of ISG20 with APOBEC3A is sufficient to diminish cccDNA; ISG20 depletion mitigates IFN-induced cccDNA loss.","method":"Transcriptome analysis; ISG20 overexpression and depletion; immunofluorescence localization; enrichment assay on deoxyuridine-ssDNA; APOBEC3A co-expression; HBV cccDNA quantification","journal":"EMBO reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ISG20 depletion and co-expression with functional readout; nucleolar localization on deaminated DNA substrate; single lab with multiple orthogonal methods","pmids":["33969602"],"is_preprint":false},{"year":2020,"finding":"ISG20 promotes degradation of nascent spliceosomal U snRNA transcripts and unstable U1 snRNA variants. ISG20 and the nuclear exosome were biochemically identified as exonucleolytic factors acting on U snRNA precursors in vitro, but KD experiments showed they act in quality control of newly synthesized U snRNAs rather than as maturation factors per se.","method":"In vitro 3'-end maturation assay (newly developed); ISG20 and nuclear exosome knockdown; 3'-end sequencing of endogenous U1 snRNA","journal":"Genes to cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro reconstitution of activity on U snRNA substrates; KD with 3'-end sequencing provides complementary cellular evidence; single lab","pmids":["33147372"],"is_preprint":false},{"year":2023,"finding":"RNA 2'O-methylation impedes ISG20-mediated RNA degradation. ISG20 pauses two nucleotides upstream of and at 2'O-methylated residues. Structure-function analysis identified ISG20 residues R53 and D90 as responsible for steric clash with 2'O-methylated nucleotides. Hypomethylated HIV-1 genomes (from FTSJ3-KO cells) are more susceptible to ISG20-mediated degradation in vitro and show impaired reverse transcription in T cells with IFN-induced ISG20.","method":"Biochemical RNA degradation assays with 2'O-methylated RNA substrates; site-directed mutagenesis of R53 and D90; FTSJ3-KO cells producing hypomethylated HIV-1; in vitro degradation comparison; T-cell infection assays with IFN","journal":"Nucleic acids research","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro reconstitution with defined methylated substrates, active-site mutagenesis (R53/D90), KO cell model, and cellular validation; multiple orthogonal approaches","pmids":["36354007"],"is_preprint":false},{"year":2016,"finding":"ISG20 inhibits influenza A virus replication in an exonuclease-dependent manner, impairing viral polymerase activity and reducing replication and transcription of viral genes. ISG20 co-localizes and directly interacts with IAV nucleoprotein (NP); the exonuclease-inactive ISG20 mutant lacks this association, indicating NP interaction depends on ISG20 exonuclease activity.","method":"Overexpression and exonuclease-inactive mutant; viral polymerase activity assay; co-localization by immunofluorescence; co-immunoprecipitation of ISG20 with NP; viral titer and protein assays","journal":"Virus genes","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — co-IP with functional mutant context; co-localization; polymerase activity assay; single lab, several orthogonal methods","pmids":["27342813"],"is_preprint":false},{"year":2023,"finding":"ISG20 degrades RHOBTB3 mRNA, increasing HIF-1α protein expression and activating NANOG signaling; ISG20 also degrades STAT1 and IRF1 mRNAs, decreasing CXCL10 expression and impairing CD8+ T cell and NK cell recruitment. These functions are downstream of HIF-1-activated ISG20 transcription in TNBC. Silencing ISG20 increases sensitivity of mouse TNBC cells to anti-PD1 immunotherapy.","method":"ISG20 KD/OE in TNBC cells; mRNA stability assays for RHOBTB3, STAT1, IRF1; HIF-1α protein measurement; NANOG reporter; CXCL10 and immune cell recruitment assays; anti-PD1 checkpoint blockade in mouse model","journal":"The Journal of experimental medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific mRNA substrate identification with decay assays; downstream signaling and immune recruitment validated; in vivo immunotherapy model; single lab","pmids":["41385111"],"is_preprint":false},{"year":2024,"finding":"Poly(A)-binding protein (PABP1) loading on the RNA 3' tail provides primary protection of cellular mRNAs against ISG20-mediated degradation. Terminal stem-loop RNA structures can also confer protection, depending on their thermodynamic stability. Histone mRNAs (non-polyadenylated, with a 3' stem-loop) show detectable ISG20-mediated decay, consistent with their lack of PABP1 loading.","method":"RNA-seq of ISG20-expressing cells; biochemical PABP1 loading assays; stem-loop stability analysis; histone mRNA quantification after ISG20 expression","journal":"Life science alliance","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq combined with biochemical assays; PABP1 protection mechanism established with multiple RNA substrates; single lab","pmids":["38418089"],"is_preprint":false},{"year":2025,"finding":"m6A modification in the EBOV genome 3'-leader region recruits m6A reader YTHDF1, which impedes ISG20 antiviral activity, thereby facilitating EBOV replication. Loss-of-function and mutational analyses confirm that m6A on the EBOV genome antagonizes ISG20 exonuclease activity.","method":"m6A mapping of EBOV genome; loss-of-function (ISG20 and YTHDF1 KD); m6A site mutations in EBOV genome; EBOV replication assays; co-immunoprecipitation of YTHDF1 with m6A-modified RNA and ISG20","journal":"International journal of biological macromolecules","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and mutational dissection of m6A-YTHDF1-ISG20 axis; single lab; consistent with mechanistic framework established for HBV","pmids":["41423124"],"is_preprint":false},{"year":2026,"finding":"ISG20 inhibits HCMV and HSV-1 replication without degrading viral RNA or DNA; instead, ISG20 expression induces an innate immune defense gene signature comprising upregulation of other ISGs, zinc finger proteins, and transposable elements, amplifying IFN production and response. JAK-STAT inhibitor ruxolitinib rescues HCMV gene expression in ISG20-expressing cells, confirming the indirect mechanism via IFN signaling amplification.","method":"Overexpression and knockdown of ISG20; RNA-seq; half-life assays of viral RNA and DNA (negative for direct degradation); ruxolitinib JAK-STAT inhibition rescue experiment; single-cell RNA-seq","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq + mechanistic rescue experiment with JAK-STAT inhibitor; direct degradation assay is negative; single lab with multiple orthogonal approaches","pmids":["41511982"],"is_preprint":false}],"current_model":"ISG20 is an IFN-inducible nuclear/cytoplasmic 3'-5' exoribonuclease (DEDDh family) that restricts a broad spectrum of RNA viruses through multiple mechanisms: (1) direct exonuclease-dependent degradation of viral ssRNA, guided by specific RNA structural features (e.g., the HBV ε stem-loop bound by ISG20's ExoIII domain) and modulated by epitranscriptomic marks (m6A-YTHDF2 promotes degradation; 2'O-methylation at R53/D90 blocks it); (2) translational inhibition of non-self RNAs linked to P-body localization; and (3) indirect amplification of the IFN response by upregulating downstream ISGs (including IFIT1), with cellular mRNAs protected from ISG20 primarily by PABP1 loading on their poly(A) tails. ISG20 transcription is driven by a unique ISRE via IRF-1 for both type I and II IFNs, and also by NF-κB in response to dsRNA."},"narrative":{"mechanistic_narrative":"ISG20 is an interferon-inducible 3'-5' exoribonuclease that restricts a broad spectrum of RNA viruses and shapes the innate immune response [PMID:11401564, PMID:12594219]. Biochemically it is a DEDDh-family exonuclease that degrades single-stranded RNA far more efficiently than DNA, using Mn2+ as cofactor; its crystal structure places it in the DEDDh group with active-site residues Met14 and Arg53 contacting the substrate ribose 2'-OH to confer RNA preference [PMID:11401564, PMID:15527770]. Its antiviral activity against RNA viruses including VSV, influenza, EMCV, HIV-1, HCV and bunyaviruses requires intact exonuclease activity [PMID:12594219, PMID:16033969, PMID:21036379, PMID:29695422]. ISG20 achieves restriction through several routes: direct, structure-guided degradation of viral RNA, exemplified by binding to the HBV epsilon stem-loop via its C-terminal ExoIII domain and degradation of HBV transcripts [PMID:28399146]; translational inhibition of non-self RNAs that correlates with localization to cytoplasmic P-bodies and spares endogenous transcripts [PMID:31600344]; and indirect amplification of the IFN program by upregulating downstream ISGs such as IFIT1 to suppress viral translation [PMID:30232164, PMID:41511982]. Substrate fate is tuned by epitranscriptomic marks: m6A modification recruits YTHDF2 to promote degradation of HBV RNA, whereas YTHDF1 binding to m6A on the EBOV genome antagonizes ISG20, and 2'O-methylation blocks degradation through steric clash with residues R53 and D90 [PMID:32059034, PMID:36354007, PMID:41423124]. Cellular mRNAs are protected primarily by PABP1 loading on their poly(A) tails [PMID:38418089]. ISG20 transcription is driven by a unique ISRE acting through IRF-1 for both type I and type II IFN, and by NF-κB in response to dsRNA [PMID:10871365, PMID:15064705]. Beyond viral defense, ISG20 participates in nuclear RNA quality control of spliceosomal U snRNAs and degrades specific cellular mRNAs (RHOBTB3, STAT1, IRF1) to modulate the tumor immune microenvironment in triple-negative breast cancer [PMID:33147372, PMID:41385111].","teleology":[{"year":2000,"claim":"Established how ISG20 expression is wired into the IFN response, defining the transcriptional logic that makes it an effector of both type I and type II IFN.","evidence":"Promoter dissection, reporter assays and EMSA for Sp-1, USF-1 and IRF-1 in cells","pmids":["10871365"],"confidence":"High","gaps":["Did not address ISG20 protein function or enzymatic role","Did not link the ISRE to any specific antiviral outcome"]},{"year":2001,"claim":"Defined ISG20 as an enzyme by reconstituting 3'-5' exonuclease activity with a strong preference for ssRNA over ssDNA, identifying its biochemical substrate.","evidence":"In vitro exonuclease assays with purified protein, metal and pH optimization","pmids":["11401564"],"confidence":"High","gaps":["No cellular substrate identified","No structural basis for RNA preference"]},{"year":2003,"claim":"Connected the enzymatic activity to a biological role by showing exonuclease-dependent restriction of RNA but not DNA viruses, establishing ISG20 as an antiviral effector.","evidence":"Overexpression of WT and active-site-dead ISG20 in HeLa cells with VSV/influenza/EMCV/adenovirus infection","pmids":["12594219"],"confidence":"High","gaps":["Did not show direct degradation of viral RNA in cells","Mechanism of viral RNA selectivity unknown"]},{"year":2004,"claim":"Resolved the structural basis of RNA substrate preference, placing ISG20 in the DEDDh family and identifying ribose-contacting residues.","evidence":"X-ray crystallography at 1.9 Å with Mn2+ and UMP plus comparison to DNase homologs","pmids":["15527770"],"confidence":"High","gaps":["No structure with a longer RNA or viral substrate","Did not address how modifications affect catalysis"]},{"year":2004,"claim":"Showed a second induction pathway via dsRNA-driven NF-κB then IRF-1, with distinct subcellular consequences, broadening the contexts that mobilize ISG20.","evidence":"Reporter assays, EMSA and fractionation comparing poly I:C versus IFN induction","pmids":["15064705"],"confidence":"Medium","gaps":["Single lab","Functional consequence of nuclear matrix enrichment not defined"]},{"year":2006,"claim":"Mapped endogenous ISG20 to nucleolar and Cajal body compartments and to snRNP/snoRNA machinery, hinting at a role beyond viral defense.","evidence":"Immunofluorescence, EM, SMN co-IP and RNA-IP for U snRNAs/U3 snoRNA","pmids":["16514659"],"confidence":"Medium","gaps":["Functional consequence of snRNA association not tested","Did not establish whether localization is required for antiviral activity"]},{"year":2010,"claim":"Extended exonuclease-dependent restriction to multiple positive-strand RNA viruses in a cell-type-specific manner and established paralog specificity.","evidence":"Ectopic expression with active-site mutant across HCV, BVDV, HAV, YFV, SARS-CoV and ISG20L1/L2 controls","pmids":["21036379"],"confidence":"Medium","gaps":["Basis of cell-type specificity unknown","No direct viral RNA degradation demonstrated"]},{"year":2016,"claim":"Identified influenza nucleoprotein as a viral interaction partner and linked ISG20 to impaired viral polymerase function.","evidence":"Co-IP and co-localization of ISG20 with IAV NP, polymerase activity assays, active-site mutant","pmids":["27342813"],"confidence":"Medium","gaps":["Single Co-IP context; NP interaction inferred to depend on activity","Direct vs indirect effect on polymerase not separated"]},{"year":2017,"claim":"Provided the clearest case of direct, structure-guided substrate recognition by mapping ISG20 binding to the HBV epsilon stem-loop via its ExoIII domain and revealing a degradation-independent restriction mode.","evidence":"EMSA direct binding, ExoIII deletion, epsilon structure mutants, catalytic-dead ISG20D94G encapsidation assays","pmids":["28399146"],"confidence":"High","gaps":["Generality of stem-loop recognition to other viruses untested","No co-structure of ISG20 bound to epsilon"]},{"year":2018,"claim":"Revealed an indirect antiviral mechanism for alphaviruses in which ISG20 amplifies ISGs like IFIT1 rather than degrading viral RNA, diversifying its mode of action.","evidence":"Inducible expression, RNA-seq, negative viral RNA degradation assay, Isg20-/- mice","pmids":["30232164"],"confidence":"Medium","gaps":["Mechanism by which ISG20 upregulates ISGs unknown","Single lab"]},{"year":2018,"claim":"Confirmed RNase-dependent antibunyaviral activity through a functional ISG screen and mapped viral sequence determinants of sensitivity.","evidence":"ISG-expression flow cytometry screen, minigenome/VLP assays, active-site mutant, in vitro viral evolution","pmids":["29695422"],"confidence":"Medium","gaps":["Why phleboviruses escape unresolved","Direct degradation of bunyaviral RNA not shown"]},{"year":2019,"claim":"Defined a translational-inhibition mechanism distinct from degradation, localized to P-bodies and based on self/non-self RNA discrimination, with KO mice confirming physiological relevance.","evidence":"Ribosome/translation assays, negative RNA stability assays, P-body live imaging, Isg20-/- mice, murine ortholog","pmids":["31600344"],"confidence":"High","gaps":["Molecular basis of self/non-self discrimination at P-bodies incomplete","Relationship between translational control and exonuclease activity not fully resolved"]},{"year":2020,"claim":"Identified the m6A-YTHDF2 axis as a cofactor system directing ISG20 to m6A-modified HBV RNA, linking epitranscriptomics to substrate selection.","evidence":"Catalytic-dead ISG20D94G co-IP of YTHDF2 and m6A RNA, methyltransferase/YTHDF2 knockdowns, HBV m6A site mutants, decay assays","pmids":["32059034"],"confidence":"High","gaps":["Whether YTHDF2 directs ISG20 to non-HBV substrates not addressed","Structural basis of the ternary complex unknown"]},{"year":2020,"claim":"Implicated ISG20 in nuclear RNA quality control of spliceosomal U snRNA precursors alongside the nuclear exosome, supporting a housekeeping function.","evidence":"In vitro 3'-end maturation assay, ISG20 and exosome knockdown, U1 snRNA 3'-end sequencing","pmids":["33147372"],"confidence":"Medium","gaps":["Relative contribution of ISG20 vs exosome unclear","Link to antiviral role not established"]},{"year":2021,"claim":"Extended ISG20 activity to deaminated HBV cccDNA, identifying it as the nuclease mediating IFN-induced cccDNA loss in cooperation with APOBEC3A.","evidence":"ISG20 depletion/co-expression, nucleolar localization, deoxyuridine-ssDNA enrichment, cccDNA quantification","pmids":["33969602"],"confidence":"Medium","gaps":["Direct nuclease action on cccDNA versus indirect effects not fully separated","Single lab"]},{"year":2023,"claim":"Established that 2'O-methylation blocks ISG20 by steric clash at R53/D90, explaining how host RNA marks and viral RNA modification status govern degradation susceptibility.","evidence":"In vitro degradation of 2'O-methylated substrates, R53/D90 mutagenesis, FTSJ3-KO hypomethylated HIV-1, T-cell infection","pmids":["36354007"],"confidence":"High","gaps":["In vivo contribution of 2'O-methylation evasion to viral fitness untested","Interplay with m6A-directed degradation not integrated"]},{"year":2023,"claim":"Revealed a pro-tumor function in which ISG20 degrades specific cellular mRNAs (RHOBTB3, STAT1, IRF1) to remodel the immune microenvironment, extending its substrate repertoire to host transcripts.","evidence":"ISG20 KD/OE in TNBC, mRNA decay assays, HIF-1α/NANOG/CXCL10 readouts, anti-PD1 mouse model","pmids":["41385111"],"confidence":"Medium","gaps":["Selectivity rules for these mRNAs versus protected transcripts unclear","Single lab"]},{"year":2024,"claim":"Defined how cellular mRNAs evade ISG20, showing PABP1 poly(A) loading and stable 3' stem-loops provide protection, completing the self/non-self discrimination model.","evidence":"RNA-seq, biochemical PABP1 loading assays, stem-loop stability analysis, histone mRNA quantification","pmids":["38418089"],"confidence":"Medium","gaps":["How viral RNAs avoid equivalent protection not fully resolved","Single lab"]},{"year":2025,"claim":"Showed that m6A can also antagonize ISG20 via YTHDF1 on the EBOV genome, demonstrating that the same mark can promote or block degradation depending on the reader.","evidence":"EBOV m6A mapping, ISG20/YTHDF1 knockdown, m6A site mutants, co-IP, replication assays","pmids":["41423124"],"confidence":"Medium","gaps":["Mechanism distinguishing YTHDF1 antagonism from YTHDF2 promotion unclear","Single lab"]},{"year":2026,"claim":"Demonstrated indirect restriction of DNA herpesviruses through IFN signaling amplification, confirmed by JAK-STAT inhibition rescue, reinforcing the non-degradative arm of ISG20 action.","evidence":"OE/KD, RNA-seq, negative viral RNA/DNA half-life assays, ruxolitinib rescue, scRNA-seq","pmids":["41511982"],"confidence":"Medium","gaps":["Molecular trigger by which ISG20 amplifies IFN unknown","Single lab"]},{"year":null,"claim":"How ISG20 integrates its multiple modes (direct degradation, translational inhibition, ISG amplification) and what determines which mode operates for a given target remains unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model linking substrate features, localization and mechanism choice","No structure of ISG20 engaging a modified or structured viral RNA","Mechanism by which catalytic-independent ISG amplification occurs unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140098","term_label":"catalytic activity, acting on RNA","supporting_discovery_ids":[0,3,8,15]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[0,1]},{"term_id":"GO:0003723","term_label":"RNA binding","supporting_discovery_ids":[0,8]}],"localization":[{"term_id":"GO:0005730","term_label":"nucleolus","supporting_discovery_ids":[6,13]},{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[6,9]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[6,11]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,3,9,20]},{"term_id":"R-HSA-8953854","term_label":"Metabolism of RNA","supporting_discovery_ids":[11,14,18]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[5,8,17]}],"complexes":["SMN complex"],"partners":["YTHDF2","YTHDF1","PABP1","IAV NP"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q96AZ6","full_name":"Interferon-stimulated gene 20 kDa protein","aliases":["Estrogen-regulated transcript 45 protein","Promyelocytic leukemia nuclear body-associated protein ISG20"],"length_aa":181,"mass_kda":20.4,"function":"Interferon-induced antiviral exoribonuclease that acts mainly on single-stranded RNA (PubMed:11401564, PubMed:12594219, PubMed:16033969). Exhibits antiviral activity against RNA viruses including hepatitis C virus (HCV), hepatitis A virus (HAV) and yellow fever virus (YFV) (PubMed:16514659, PubMed:21036379). Inhibition of several viruses such as chikungunya virus (CHIKV) does not involve the degradation of viral RNAs, but rather the inhibition of translation of viral proteins (By similarity). Exerts a translational control over a large panel of non-self RNA substrates while sparing endogenous transcripts. This activity correlates with the protein's ability to localize in cytoplasmic processing bodies (PubMed:31600344). May also act as master regulator of over hundred interferon stimulated genes leading to viral genome translation inhibition (By similarity). May play additional roles in the maturation of snRNAs and rRNAs, and in ribosome biogenesis (PubMed:16514659)","subcellular_location":"Nucleus; Nucleus, nucleolus; Cytoplasm; Nucleus, Cajal body; Cytoplasm, P-body","url":"https://www.uniprot.org/uniprotkb/Q96AZ6/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ISG20","classification":"Not Classified","n_dependent_lines":1,"n_total_lines":1208,"dependency_fraction":0.0008278145695364238},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ISG20","total_profiled":1310},"omim":[{"mim_id":"611930","title":"INTERFERON-STIMULATED EXONUCLEASE GENE 20-KD-LIKE 2; ISG20L2","url":"https://www.omim.org/entry/611930"},{"mim_id":"609676","title":"MITOCHONDRIAL ANTIVIRAL SIGNALING PROTEIN; MAVS","url":"https://www.omim.org/entry/609676"},{"mim_id":"609532","title":"HEPATITIS C VIRUS, SUSCEPTIBILITY TO","url":"https://www.omim.org/entry/609532"},{"mim_id":"604533","title":"INTERFERON-STIMULATED EXONUCLEASE GENE 20; ISG20","url":"https://www.omim.org/entry/604533"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":176.6}],"url":"https://www.proteinatlas.org/search/ISG20"},"hgnc":{"alias_symbol":["HEM45","CD25"],"prev_symbol":[]},"alphafold":{"accession":"Q96AZ6","domains":[{"cath_id":"3.30.420.10","chopping":"6-171","consensus_level":"high","plddt":97.6052,"start":6,"end":171}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96AZ6","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q96AZ6-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q96AZ6-F1-predicted_aligned_error_v6.png","plddt_mean":95.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ISG20","jax_strain_url":"https://www.jax.org/strain/search?query=ISG20"},"sequence":{"accession":"Q96AZ6","fasta_url":"https://rest.uniprot.org/uniprotkb/Q96AZ6.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q96AZ6/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q96AZ6"}},"corpus_meta":[{"pmid":"12594219","id":"PMC_12594219","title":"ISG20, a new interferon-induced RNase specific for single-stranded RNA, defines an alternative antiviral pathway against RNA genomic viruses.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12594219","citation_count":191,"is_preprint":false},{"pmid":"28399146","id":"PMC_28399146","title":"Interferon-inducible ribonuclease ISG20 inhibits hepatitis B virus replication through directly binding to the epsilon stem-loop structure of viral RNA.","date":"2017","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/28399146","citation_count":118,"is_preprint":false},{"pmid":"32059034","id":"PMC_32059034","title":"Interferon-stimulated gene 20 (ISG20) selectively degrades N6-methyladenosine modified Hepatitis B Virus transcripts.","date":"2020","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/32059034","citation_count":116,"is_preprint":false},{"pmid":"11401564","id":"PMC_11401564","title":"The human interferon- and estrogen-regulated ISG20/HEM45 gene product degrades single-stranded RNA and DNA in vitro.","date":"2001","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11401564","citation_count":97,"is_preprint":false},{"pmid":"21036379","id":"PMC_21036379","title":"Antiviral activities of ISG20 in positive-strand RNA virus infections.","date":"2010","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/21036379","citation_count":84,"is_preprint":false},{"pmid":"16033969","id":"PMC_16033969","title":"Interferon-induced exonuclease ISG20 exhibits an antiviral activity against human immunodeficiency virus type 1.","date":"2005","source":"The Journal of general virology","url":"https://pubmed.ncbi.nlm.nih.gov/16033969","citation_count":83,"is_preprint":false},{"pmid":"29899085","id":"PMC_29899085","title":"Lnc-ISG20 Inhibits Influenza A Virus Replication by Enhancing ISG20 Expression.","date":"2018","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/29899085","citation_count":78,"is_preprint":false},{"pmid":"10871365","id":"PMC_10871365","title":"A unique ISRE, in the TATA-less human Isg20 promoter, confers IRF-1-mediated responsiveness to both interferon type I and type II.","date":"2000","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/10871365","citation_count":73,"is_preprint":false},{"pmid":"30232164","id":"PMC_30232164","title":"The Interferon-Induced Exonuclease ISG20 Exerts Antiviral Activity through Upregulation of Type I Interferon Response Proteins.","date":"2018","source":"mSphere","url":"https://pubmed.ncbi.nlm.nih.gov/30232164","citation_count":63,"is_preprint":false},{"pmid":"17445960","id":"PMC_17445960","title":"ISG20, an actor of the innate immune response.","date":"2007","source":"Biochimie","url":"https://pubmed.ncbi.nlm.nih.gov/17445960","citation_count":57,"is_preprint":false},{"pmid":"31600344","id":"PMC_31600344","title":"The interferon stimulated gene 20 protein (ISG20) is an innate defense antiviral factor that discriminates self versus non-self translation.","date":"2019","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/31600344","citation_count":55,"is_preprint":false},{"pmid":"33969602","id":"PMC_33969602","title":"Interferon-induced degradation of the persistent hepatitis B virus cccDNA form depends on ISG20.","date":"2021","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/33969602","citation_count":55,"is_preprint":false},{"pmid":"35174977","id":"PMC_35174977","title":"ISG20: an enigmatic antiviral RNase targeting multiple viruses.","date":"2022","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/35174977","citation_count":54,"is_preprint":false},{"pmid":"15527770","id":"PMC_15527770","title":"Crystal structure of human ISG20, an interferon-induced antiviral ribonuclease.","date":"2004","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/15527770","citation_count":53,"is_preprint":false},{"pmid":"27342813","id":"PMC_27342813","title":"Influenza A Virus-induced expression of ISG20 inhibits viral replication by interacting with nucleoprotein.","date":"2016","source":"Virus genes","url":"https://pubmed.ncbi.nlm.nih.gov/27342813","citation_count":49,"is_preprint":false},{"pmid":"29695422","id":"PMC_29695422","title":"Interferon-Stimulated Gene (ISG)-Expression Screening Reveals the Specific Antibunyaviral Activity of ISG20.","date":"2018","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/29695422","citation_count":46,"is_preprint":false},{"pmid":"32003757","id":"PMC_32003757","title":"ISG20 serves as a potential biomarker and drives tumor progression in clear cell renal cell carcinoma.","date":"2020","source":"Aging","url":"https://pubmed.ncbi.nlm.nih.gov/32003757","citation_count":43,"is_preprint":false},{"pmid":"15064705","id":"PMC_15064705","title":"The exonuclease ISG20 is directly induced by synthetic dsRNA via NF-kappaB and IRF1 activation.","date":"2004","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/15064705","citation_count":41,"is_preprint":false},{"pmid":"27626689","id":"PMC_27626689","title":"Interferon-stimulated gene of 20 kDa protein (ISG20) degrades RNA of hepatitis B virus to impede the replication of HBV in vitro and in vivo.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/27626689","citation_count":37,"is_preprint":false},{"pmid":"9569007","id":"PMC_9569007","title":"Expression and estrogen regulation of the HEM45 MRNA in human tumor lines and in the rat uterus.","date":"1998","source":"The Journal of steroid biochemistry and molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/9569007","citation_count":36,"is_preprint":false},{"pmid":"33939247","id":"PMC_33939247","title":"LncRNA lnc-ISG20 promotes renal fibrosis in diabetic nephropathy by inducing AKT phosphorylation through miR-486-5p/NFAT5.","date":"2021","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/33939247","citation_count":35,"is_preprint":false},{"pmid":"28357179","id":"PMC_28357179","title":"Interferon-stimulated gene 20-kDa protein (ISG20) in infection and disease: Review and outlook.","date":"2017","source":"Intractable & rare diseases research","url":"https://pubmed.ncbi.nlm.nih.gov/28357179","citation_count":32,"is_preprint":false},{"pmid":"16514659","id":"PMC_16514659","title":"The exonuclease ISG20 mainly localizes in the nucleolus and the Cajal (Coiled) bodies and is associated with nuclear SMN protein-containing complexes.","date":"2006","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16514659","citation_count":32,"is_preprint":false},{"pmid":"36354007","id":"PMC_36354007","title":"Internal RNA 2'O-methylation in the HIV-1 genome counteracts ISG20 nuclease-mediated antiviral effect.","date":"2023","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/36354007","citation_count":24,"is_preprint":false},{"pmid":"38761779","id":"PMC_38761779","title":"TGF β1 promotes the polarization of M2-type macrophages and activates PI3K/mTOR signaling pathway by inhibiting ISG20 to sensitize ovarian cancer to cisplatin.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/38761779","citation_count":24,"is_preprint":false},{"pmid":"34078871","id":"PMC_34078871","title":"Disruption of STAT5A and NMI signaling axis leads to ISG20-driven metastatic mammary tumors.","date":"2021","source":"Oncogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/34078871","citation_count":24,"is_preprint":false},{"pmid":"19321657","id":"PMC_19321657","title":"Prevention of embryo loss in non-obese diabetic mice using adoptive ITGA2(+)ISG20(+) natural killer-cell transfer.","date":"2009","source":"Reproduction (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/19321657","citation_count":22,"is_preprint":false},{"pmid":"37342328","id":"PMC_37342328","title":"ISG20 stimulates anti-tumor immunity via a double-stranded RNA-induced interferon response in ovarian cancer.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37342328","citation_count":21,"is_preprint":false},{"pmid":"37452495","id":"PMC_37452495","title":"Targeting RNA oxidation by ISG20-mediated degradation is a potential therapeutic strategy for acute kidney injury.","date":"2023","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37452495","citation_count":18,"is_preprint":false},{"pmid":"18278447","id":"PMC_18278447","title":"Cloning, eukaryotic expression of human ISG20 and preliminary study on the effect of its anti-HBV.","date":"2008","source":"Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban","url":"https://pubmed.ncbi.nlm.nih.gov/18278447","citation_count":16,"is_preprint":false},{"pmid":"37340981","id":"PMC_37340981","title":"Expression of interferon-stimulated gene 20 (ISG20), an antiviral effector protein, in glomerular endothelial cells: possible involvement of ISG20 in lupus nephritis.","date":"2023","source":"Renal failure","url":"https://pubmed.ncbi.nlm.nih.gov/37340981","citation_count":13,"is_preprint":false},{"pmid":"39073688","id":"PMC_39073688","title":"FOSL2-mediated transcription of ISG20 induces M2 polarization of macrophages and enhances tumorigenic ability of glioblastoma cells.","date":"2024","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39073688","citation_count":12,"is_preprint":false},{"pmid":"23794439","id":"PMC_23794439","title":"Differential expression of ISG20 in chronic hepatitis B patients and relation to interferon-alpha therapy response.","date":"2013","source":"Journal of medical virology","url":"https://pubmed.ncbi.nlm.nih.gov/23794439","citation_count":12,"is_preprint":false},{"pmid":"29259855","id":"PMC_29259855","title":"Estradiol and proinflammatory cytokines stimulate ISG20 expression in synovial fibroblasts of patients with osteoarthritis.","date":"2017","source":"Intractable & rare diseases research","url":"https://pubmed.ncbi.nlm.nih.gov/29259855","citation_count":11,"is_preprint":false},{"pmid":"35513266","id":"PMC_35513266","title":"ISG20 inhibits bluetongue virus replication.","date":"2022","source":"Virologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/35513266","citation_count":10,"is_preprint":false},{"pmid":"32782682","id":"PMC_32782682","title":"ISG20 is overexpressed in clinically relevant radioresistant oral cancer cells.","date":"2020","source":"International journal of clinical and experimental pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32782682","citation_count":10,"is_preprint":false},{"pmid":"36177004","id":"PMC_36177004","title":"The regulation of ISG20 expression on SARS-CoV-2 infection in cancer patients and healthy individuals.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36177004","citation_count":8,"is_preprint":false},{"pmid":"34769072","id":"PMC_34769072","title":"Establishment of a Rapid Detection System for ISG20-Dependent SARS-CoV-2 Subreplicon RNA Degradation Induced by Interferon-α.","date":"2021","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/34769072","citation_count":8,"is_preprint":false},{"pmid":"38685521","id":"PMC_38685521","title":"The PTPRZ1-MET/STAT3/ISG20 axis in glioma stem-like cells modulates tumor-associated macrophage polarization.","date":"2024","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/38685521","citation_count":7,"is_preprint":false},{"pmid":"38418089","id":"PMC_38418089","title":"Stable structures or PABP1 loading protects cellular and viral RNAs against ISG20-mediated decay.","date":"2024","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/38418089","citation_count":6,"is_preprint":false},{"pmid":"33147372","id":"PMC_33147372","title":"ISG20 and nuclear exosome promote destabilization of nascent transcripts for spliceosomal U snRNAs and U1 variants.","date":"2020","source":"Genes to cells : devoted to molecular & cellular mechanisms","url":"https://pubmed.ncbi.nlm.nih.gov/33147372","citation_count":5,"is_preprint":false},{"pmid":"39971662","id":"PMC_39971662","title":"Not all RNAs are created equal for the antiviral RNase ISG20.","date":"2025","source":"Trends in microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/39971662","citation_count":4,"is_preprint":false},{"pmid":"40644925","id":"PMC_40644925","title":"Activation of sclerostin inhibits Isg20-Mediated aerobic glycolysis ameliorating renal Fibrosis: the renoprotective mechanism of hederagenin in CKD.","date":"2025","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/40644925","citation_count":3,"is_preprint":false},{"pmid":"37058744","id":"PMC_37058744","title":"Characterization of the induction kinetics and antiviral functions of IRF1, ISG15 and ISG20 in cells infected with gammacoronavirus avian infectious bronchitis virus.","date":"2023","source":"Virology","url":"https://pubmed.ncbi.nlm.nih.gov/37058744","citation_count":3,"is_preprint":false},{"pmid":"23663760","id":"PMC_23663760","title":"[Antiviral activities of ISG20 against hepatitis C virus].","date":"2013","source":"Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/23663760","citation_count":3,"is_preprint":false},{"pmid":"28818749","id":"PMC_28818749","title":"A conjugate protein containing HIV TAT, ISG20, and a PRRSV polymerase binding inhibits PRRSV replication and may be a novel therapeutic platform.","date":"2017","source":"Research in veterinary science","url":"https://pubmed.ncbi.nlm.nih.gov/28818749","citation_count":2,"is_preprint":false},{"pmid":"41385111","id":"PMC_41385111","title":"HIF-1-mediated ISG20 expression promotes breast cancer stemness and immune evasion.","date":"2025","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41385111","citation_count":1,"is_preprint":false},{"pmid":"41415292","id":"PMC_41415292","title":"Causal inference of CLEC5A and ISG20 in atherosclerosis: integrating Mendelian randomization and eQTL evidence.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/41415292","citation_count":1,"is_preprint":false},{"pmid":"41583555","id":"PMC_41583555","title":"Therapeutic potential of ISG20 in attenuating podocyte injury via inhibition of ferroptosis.","date":"2025","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/41583555","citation_count":1,"is_preprint":false},{"pmid":"40937574","id":"PMC_40937574","title":"ISG20: The multifaceted 'molecular star' in cancer research (Review).","date":"2025","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/40937574","citation_count":0,"is_preprint":false},{"pmid":"41511982","id":"PMC_41511982","title":"Exonuclease ISG20 inhibits human cytomegalovirus replication by inducing an innate immune defense signature.","date":"2026","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/41511982","citation_count":0,"is_preprint":false},{"pmid":"41304224","id":"PMC_41304224","title":"ISG20 Restricts BK Polyomavirus Infection and Engages in Reciprocal Regulation with Viral Large T Antigen.","date":"2025","source":"Microorganisms","url":"https://pubmed.ncbi.nlm.nih.gov/41304224","citation_count":0,"is_preprint":false},{"pmid":"40622935","id":"PMC_40622935","title":"Targeting interferon-stimulated gene of 20 kDa protein (Isg20) inhibits ribosome biogenesis to ameliorate the progression of renal fibrosis.","date":"2025","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/40622935","citation_count":0,"is_preprint":false},{"pmid":"41423124","id":"PMC_41423124","title":"m6A modification in the 3'‑leader region of EBOV genome antagonizes ISG20 to facilitate viral replication.","date":"2025","source":"International journal of biological macromolecules","url":"https://pubmed.ncbi.nlm.nih.gov/41423124","citation_count":0,"is_preprint":false},{"pmid":"36795687","id":"PMC_36795687","title":"Correction: The interferon stimulated gene 20 protein (ISG20) is an innate defense antiviral factor that discriminates self versus non-self translation.","date":"2023","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/36795687","citation_count":0,"is_preprint":false},{"pmid":"40484065","id":"PMC_40484065","title":"Structural features, transcriptional profiles, and potential roles in antiviral immunity of interferon-stimulated 20-kDa exonuclease (ISG20) in red-spotted grouper (Epinephelus akaara).","date":"2025","source":"Fish & shellfish immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40484065","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.23.650160","title":"A New Serological Autoantibody Signature Associated with Multiple Sclerosis","date":"2025-04-26","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.23.650160","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.04.13.648563","title":"Sustained Antigen Stimulation to Evoke and Study Negative feedback Systems responsible for Self-Tolerance/Tumor Immune Escape and transition to the M2 macrophage","date":"2025-04-18","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.13.648563","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.28.615513","title":"Exploring the Correlation Between UVB Sensitivity and SLE Activity: Insights into UVB-Driven Pathogenesis in Lupus Erythematosus","date":"2024-09-30","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.28.615513","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.26.605349","title":"Proliferative arrest induces neuronal differentiation and innate immune responses in normal and Creutzfeldt-Jakob Disease agent (CJ) infected rat septal neurons","date":"2024-07-29","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.26.605349","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":32348,"output_tokens":6076,"usd":0.094092,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14752,"output_tokens":5647,"usd":0.107467,"stage2_stop_reason":"end_turn"},"total_usd":0.201559,"stage1_batch_id":"msgbatch_0147LFpL5iCPFZF66xp23BqC","stage2_batch_id":"msgbatch_01Crtwc6eCsZh1CrnfJhY7J7","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"ISG20/HEM45 protein functions as a 3' to 5' exonuclease in vitro, displaying a pH optimum of ~7.0, preferring Mn2+ as a metal cofactor, and degrading single-stranded RNA at a rate approximately 35-fold higher than single-stranded DNA.\",\n      \"method\": \"In vitro biochemical exonuclease assay with purified protein; metal cofactor and pH optimization experiments\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — direct in vitro reconstitution of enzymatic activity with defined substrates, metal cofactor characterization, and quantitative rate comparisons\",\n      \"pmids\": [\"11401564\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"Crystal structure of human ISG20 at 1.9 Å resolution reveals it complexed with two Mn2+ ions and UMP; it belongs to the DEDDh group of RNases and its active site is structurally similar to DNases (E. coli DNA Pol III ε subunit and Exo I). Distinctive residues Met14 and Arg53 form hydrogen bonds with the 2'-OH of the UMP ribose, likely conferring RNA substrate preference.\",\n      \"method\": \"X-ray crystallography at 1.9 Å with Mn2+ and UMP ligands; structural comparison with homologs\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — crystal structure with bound substrate analog and metal cofactors; active site residues identified and compared to mechanistically characterized homologs\",\n      \"pmids\": [\"15527770\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"The ISG20 promoter lacks TATA and CAAT elements; basal transcriptional activity depends on Sp-1 and USF-1. A unique ISRE mediates both type I and type II IFN induction strictly dependent on IRF-1, and this ISRE also contributes to constitutive transcriptional activity.\",\n      \"method\": \"Promoter cloning, deletion analysis, reporter assays, EMSA for Sp-1, USF-1, and IRF-1 binding; dominant-negative and overexpression of transcription factors\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal promoter dissection methods (reporter assays + EMSA + factor manipulation) in a single rigorous study\",\n      \"pmids\": [\"10871365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"ISG20 exerts antiviral activity against RNA genomic viruses (VSV, influenza, EMCV) but not DNA adenovirus; it specifically inhibits VSV mRNA synthesis and protein production. Antiviral effect requires exonuclease activity, as the exonuclease-inactive mutant has no antiviral effect. The inactive mutant can inhibit ISG20 exonuclease activity in vitro (dominant-negative), and its expression reduces IFN-mediated VSV inhibition.\",\n      \"method\": \"Overexpression of wild-type and exonuclease-inactive ISG20 in HeLa cells; viral infection assays; mRNA and protein synthesis analysis; in vitro exonuclease inhibition by dominant-negative mutant\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — active-site mutagenesis linked to cellular antiviral phenotype; dominant-negative in vitro validation; multiple RNA viruses tested\",\n      \"pmids\": [\"12594219\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"ISG20 induction by synthetic dsRNA (poly I:C) is stronger and faster than by IFN. Transcriptional activation of ISG20 by dsRNA involves initial NF-κB (p50/p65) binding to a κB element followed by IRF-1 binding to the ISRE. Contrary to IFN, dsRNA induces nuclear matrix enrichment of ISG20.\",\n      \"method\": \"Reporter assays; EMSA; chromatin-based binding assays; immunofluorescence/subcellular fractionation\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA and reporter assays in a single lab; two transcription factor pathways identified with orthogonal methods\",\n      \"pmids\": [\"15064705\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"ISG20 inhibits HIV-1 replication; antiviral effect requires the exonuclease activity of ISG20, as exonuclease-inactive mutant ISG20 shows no antiviral effect. HIV-1-induced apoptosis is significantly reduced in cells infected with HIV-1 expressing ISG20.\",\n      \"method\": \"HIV-1-derived virus expressing ISG20 (HIV-1NL4-3ISG20); replication kinetics in CEM cells and PBMCs; exonuclease-inactive mutant comparison\",\n      \"journal\": \"The Journal of general virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — active-site mutagenesis linked to antiviral phenotype; single lab with clear genetic controls\",\n      \"pmids\": [\"16033969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Endogenous ISG20 localizes predominantly to the nucleolus (dense fibrillar component, the major site for rRNA processing) and Cajal bodies, in addition to diffuse cytoplasmic and nucleoplasmic distribution. ISG20 is associated with SMN-containing macromolecular nuclear complexes and with U1, U2 snRNAs, and U3 snoRNA. IFN treatment increases ISG20 accumulation in Cajal bodies.\",\n      \"method\": \"Immunofluorescence, electron microscopy, co-immunoprecipitation of SMN complexes, RNA immunoprecipitation for snRNAs/snoRNAs, coilin-dsRed coexpression\",\n      \"journal\": \"Journal of cellular biochemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple imaging and biochemical methods in single lab; endogenous protein localization with functional nuclear complex association\",\n      \"pmids\": [\"16514659\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"ISG20 inhibits positive-strand RNA viruses including HCV, bovine viral diarrhea virus, hepatitis A virus, and yellow fever virus in a cell-type-specific manner, but not SARS-CoV in Huh7.5 cells. All antiviral effects require exonuclease activity. The closely related paralogs ISG20L1 and ISG20L2 do not inhibit HCV replication.\",\n      \"method\": \"Ectopic overexpression; exonuclease-inactive mutant comparison; viral replication assays across multiple virus families and cell types\",\n      \"journal\": \"Virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — active-site mutagenesis confirms mechanistic requirement across multiple viruses; paralog specificity established; single lab\",\n      \"pmids\": [\"21036379\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"ISG20 inhibits HBV replication by degrading HBV RNA. The susceptibility element was mapped to the HBV RNA terminal redundant region containing the epsilon (ε) stem-loop. ISG20 binds the ε stem-loop directly in vitro in the absence of other cellular proteins (EMSA), with the lower stem portion of ε being the major binding site. The C-terminal ExoIII domain of ISG20 is responsible for ε binding; deletion of ExoIII abolishes in vitro binding and intracellular HBV RNA degradation. Enzymatic-inactive ISG20D94G retains antiviral activity by preventing pgRNA encapsidation via ISG20-ε interaction even without degradation.\",\n      \"method\": \"EMSA (direct binding); ExoIII domain deletion; HBV ε structure mutants; ISG20D94G catalytic mutant; encapsidation assays; cellular HBV RNA decay assays\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro direct binding by EMSA, domain deletion mapping, catalytic mutant, structural mutants of RNA target; multiple orthogonal methods in single rigorous study\",\n      \"pmids\": [\"28399146\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ISG20 localizes primarily to Cajal bodies in the nucleus when ectopically expressed. In the context of alphavirus restriction, ISG20 does not directly degrade viral RNAs; instead, it upregulates over 100 other genes including IFIT1, an ISG that suppresses translation of alphavirus RNAs, leading to indirect inhibition of viral RNA translation.\",\n      \"method\": \"Inducible ectopic expression system; Isg20-/- mice; RNA-seq of ISG20-expressing cells; viral RNA degradation assays (negative finding for direct RNA degradation); IFIT1 protein quantification; alphavirus replication assays in wild-type vs Isg20-/- mice\",\n      \"journal\": \"mSphere\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO mice + ectopic expression + RNA-seq; direct RNA degradation assay is negative; indirect mechanism supported by multiple approaches in single lab\",\n      \"pmids\": [\"30232164\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"ISG20 exhibits potent antibunyaviral activity (Peribunyaviridae, Hantaviridae, Nairoviridae) but phleboviruses largely escape inhibition. Antibunyaviral activity depends on RNase activity. In vitro evolution of resistant BUNV mapped sequence determinants of ISG20 sensitivity/resistance.\",\n      \"method\": \"ISG-expression flow cytometry screen of ~500 ISGs; minigenome/VLP assay; exonuclease-inactive mutant; in vitro viral evolution for resistance mapping\",\n      \"journal\": \"Journal of virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional screen validated with mechanistic assays; RNase activity requirement confirmed by mutagenesis; viral resistance determinants mapped\",\n      \"pmids\": [\"29695422\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"ISG20 inhibits VSV replication by decreasing viral protein synthesis without degrading viral RNA. ISG20 exerts translational control over non-self RNAs (including those from transfected DNA) while sparing endogenous transcripts. This activity correlates with ISG20's localization in cytoplasmic processing bodies (P-bodies). Murine ISG20 ortholog functions similarly; Isg20-/- mice show increased susceptibility to viral infection.\",\n      \"method\": \"VSV infection assays; ribosome profiling / translation assays; viral RNA stability assays (negative for degradation); subcellular localization by live imaging to P-bodies; Isg20-/- mouse infection model; non-self RNA transfection controls\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (translation assay, RNA stability, P-body localization, KO mice); self/non-self discrimination established; replicated with murine ortholog\",\n      \"pmids\": [\"31600344\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"m6A-modified HBV transcripts are selectively recognized and degraded by ISG20. The m6A reader protein YTHDF2 acts as a cofactor: ISG20 forms a complex with YTHDF2 and m6A-modified HBV RNA (demonstrated using enzymatically inactive ISG20D94G). Silencing of m6A methyltransferases or YTHDF2 reduces ISG20-mediated HBV RNA degradation. m6A at position A1907 within the ε stem-loops is the critical site.\",\n      \"method\": \"ISG20D94G co-immunoprecipitation of YTHDF2 and m6A RNA; methyltransferase knockdown; YTHDF2 knockdown; HBV m6A site mutants (5', 3', both termini); HBV RNA decay assays\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — catalytic mutant trapping of complex, RNA mutants, multiple knockdowns; two orthogonal labs (Siddiqui group + earlier Liu/Guo work); complex mechanistically defined\",\n      \"pmids\": [\"32059034\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ISG20 is required for IFN-induced degradation of HBV cccDNA. ISG20 is the only type I and II IFN-induced nuclear protein with annotated nuclease activity. ISG20 localizes to nucleoli of IFN-stimulated hepatocytes and is enriched on deoxyuridine-containing ssDNA mimicking APOBEC3A-deaminated HBV DNA. Co-expression of ISG20 with APOBEC3A is sufficient to diminish cccDNA; ISG20 depletion mitigates IFN-induced cccDNA loss.\",\n      \"method\": \"Transcriptome analysis; ISG20 overexpression and depletion; immunofluorescence localization; enrichment assay on deoxyuridine-ssDNA; APOBEC3A co-expression; HBV cccDNA quantification\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ISG20 depletion and co-expression with functional readout; nucleolar localization on deaminated DNA substrate; single lab with multiple orthogonal methods\",\n      \"pmids\": [\"33969602\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ISG20 promotes degradation of nascent spliceosomal U snRNA transcripts and unstable U1 snRNA variants. ISG20 and the nuclear exosome were biochemically identified as exonucleolytic factors acting on U snRNA precursors in vitro, but KD experiments showed they act in quality control of newly synthesized U snRNAs rather than as maturation factors per se.\",\n      \"method\": \"In vitro 3'-end maturation assay (newly developed); ISG20 and nuclear exosome knockdown; 3'-end sequencing of endogenous U1 snRNA\",\n      \"journal\": \"Genes to cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro reconstitution of activity on U snRNA substrates; KD with 3'-end sequencing provides complementary cellular evidence; single lab\",\n      \"pmids\": [\"33147372\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"RNA 2'O-methylation impedes ISG20-mediated RNA degradation. ISG20 pauses two nucleotides upstream of and at 2'O-methylated residues. Structure-function analysis identified ISG20 residues R53 and D90 as responsible for steric clash with 2'O-methylated nucleotides. Hypomethylated HIV-1 genomes (from FTSJ3-KO cells) are more susceptible to ISG20-mediated degradation in vitro and show impaired reverse transcription in T cells with IFN-induced ISG20.\",\n      \"method\": \"Biochemical RNA degradation assays with 2'O-methylated RNA substrates; site-directed mutagenesis of R53 and D90; FTSJ3-KO cells producing hypomethylated HIV-1; in vitro degradation comparison; T-cell infection assays with IFN\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro reconstitution with defined methylated substrates, active-site mutagenesis (R53/D90), KO cell model, and cellular validation; multiple orthogonal approaches\",\n      \"pmids\": [\"36354007\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ISG20 inhibits influenza A virus replication in an exonuclease-dependent manner, impairing viral polymerase activity and reducing replication and transcription of viral genes. ISG20 co-localizes and directly interacts with IAV nucleoprotein (NP); the exonuclease-inactive ISG20 mutant lacks this association, indicating NP interaction depends on ISG20 exonuclease activity.\",\n      \"method\": \"Overexpression and exonuclease-inactive mutant; viral polymerase activity assay; co-localization by immunofluorescence; co-immunoprecipitation of ISG20 with NP; viral titer and protein assays\",\n      \"journal\": \"Virus genes\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — co-IP with functional mutant context; co-localization; polymerase activity assay; single lab, several orthogonal methods\",\n      \"pmids\": [\"27342813\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"ISG20 degrades RHOBTB3 mRNA, increasing HIF-1α protein expression and activating NANOG signaling; ISG20 also degrades STAT1 and IRF1 mRNAs, decreasing CXCL10 expression and impairing CD8+ T cell and NK cell recruitment. These functions are downstream of HIF-1-activated ISG20 transcription in TNBC. Silencing ISG20 increases sensitivity of mouse TNBC cells to anti-PD1 immunotherapy.\",\n      \"method\": \"ISG20 KD/OE in TNBC cells; mRNA stability assays for RHOBTB3, STAT1, IRF1; HIF-1α protein measurement; NANOG reporter; CXCL10 and immune cell recruitment assays; anti-PD1 checkpoint blockade in mouse model\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific mRNA substrate identification with decay assays; downstream signaling and immune recruitment validated; in vivo immunotherapy model; single lab\",\n      \"pmids\": [\"41385111\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Poly(A)-binding protein (PABP1) loading on the RNA 3' tail provides primary protection of cellular mRNAs against ISG20-mediated degradation. Terminal stem-loop RNA structures can also confer protection, depending on their thermodynamic stability. Histone mRNAs (non-polyadenylated, with a 3' stem-loop) show detectable ISG20-mediated decay, consistent with their lack of PABP1 loading.\",\n      \"method\": \"RNA-seq of ISG20-expressing cells; biochemical PABP1 loading assays; stem-loop stability analysis; histone mRNA quantification after ISG20 expression\",\n      \"journal\": \"Life science alliance\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq combined with biochemical assays; PABP1 protection mechanism established with multiple RNA substrates; single lab\",\n      \"pmids\": [\"38418089\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"m6A modification in the EBOV genome 3'-leader region recruits m6A reader YTHDF1, which impedes ISG20 antiviral activity, thereby facilitating EBOV replication. Loss-of-function and mutational analyses confirm that m6A on the EBOV genome antagonizes ISG20 exonuclease activity.\",\n      \"method\": \"m6A mapping of EBOV genome; loss-of-function (ISG20 and YTHDF1 KD); m6A site mutations in EBOV genome; EBOV replication assays; co-immunoprecipitation of YTHDF1 with m6A-modified RNA and ISG20\",\n      \"journal\": \"International journal of biological macromolecules\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and mutational dissection of m6A-YTHDF1-ISG20 axis; single lab; consistent with mechanistic framework established for HBV\",\n      \"pmids\": [\"41423124\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"ISG20 inhibits HCMV and HSV-1 replication without degrading viral RNA or DNA; instead, ISG20 expression induces an innate immune defense gene signature comprising upregulation of other ISGs, zinc finger proteins, and transposable elements, amplifying IFN production and response. JAK-STAT inhibitor ruxolitinib rescues HCMV gene expression in ISG20-expressing cells, confirming the indirect mechanism via IFN signaling amplification.\",\n      \"method\": \"Overexpression and knockdown of ISG20; RNA-seq; half-life assays of viral RNA and DNA (negative for direct degradation); ruxolitinib JAK-STAT inhibition rescue experiment; single-cell RNA-seq\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq + mechanistic rescue experiment with JAK-STAT inhibitor; direct degradation assay is negative; single lab with multiple orthogonal approaches\",\n      \"pmids\": [\"41511982\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ISG20 is an IFN-inducible nuclear/cytoplasmic 3'-5' exoribonuclease (DEDDh family) that restricts a broad spectrum of RNA viruses through multiple mechanisms: (1) direct exonuclease-dependent degradation of viral ssRNA, guided by specific RNA structural features (e.g., the HBV ε stem-loop bound by ISG20's ExoIII domain) and modulated by epitranscriptomic marks (m6A-YTHDF2 promotes degradation; 2'O-methylation at R53/D90 blocks it); (2) translational inhibition of non-self RNAs linked to P-body localization; and (3) indirect amplification of the IFN response by upregulating downstream ISGs (including IFIT1), with cellular mRNAs protected from ISG20 primarily by PABP1 loading on their poly(A) tails. ISG20 transcription is driven by a unique ISRE via IRF-1 for both type I and II IFNs, and also by NF-κB in response to dsRNA.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ISG20 is an interferon-inducible 3'-5' exoribonuclease that restricts a broad spectrum of RNA viruses and shapes the innate immune response [#0, #3]. Biochemically it is a DEDDh-family exonuclease that degrades single-stranded RNA far more efficiently than DNA, using Mn2+ as cofactor; its crystal structure places it in the DEDDh group with active-site residues Met14 and Arg53 contacting the substrate ribose 2'-OH to confer RNA preference [#0, #1]. Its antiviral activity against RNA viruses including VSV, influenza, EMCV, HIV-1, HCV and bunyaviruses requires intact exonuclease activity [#3, #5, #7, #10]. ISG20 achieves restriction through several routes: direct, structure-guided degradation of viral RNA, exemplified by binding to the HBV epsilon stem-loop via its C-terminal ExoIII domain and degradation of HBV transcripts [#8]; translational inhibition of non-self RNAs that correlates with localization to cytoplasmic P-bodies and spares endogenous transcripts [#11]; and indirect amplification of the IFN program by upregulating downstream ISGs such as IFIT1 to suppress viral translation [#9, #20]. Substrate fate is tuned by epitranscriptomic marks: m6A modification recruits YTHDF2 to promote degradation of HBV RNA, whereas YTHDF1 binding to m6A on the EBOV genome antagonizes ISG20, and 2'O-methylation blocks degradation through steric clash with residues R53 and D90 [#12, #15, #19]. Cellular mRNAs are protected primarily by PABP1 loading on their poly(A) tails [#18]. ISG20 transcription is driven by a unique ISRE acting through IRF-1 for both type I and type II IFN, and by NF-\\u03baB in response to dsRNA [#2, #4]. Beyond viral defense, ISG20 participates in nuclear RNA quality control of spliceosomal U snRNAs and degrades specific cellular mRNAs (RHOBTB3, STAT1, IRF1) to modulate the tumor immune microenvironment in triple-negative breast cancer [#14, #17].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Established how ISG20 expression is wired into the IFN response, defining the transcriptional logic that makes it an effector of both type I and type II IFN.\",\n      \"evidence\": \"Promoter dissection, reporter assays and EMSA for Sp-1, USF-1 and IRF-1 in cells\",\n      \"pmids\": [\"10871365\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not address ISG20 protein function or enzymatic role\", \"Did not link the ISRE to any specific antiviral outcome\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Defined ISG20 as an enzyme by reconstituting 3'-5' exonuclease activity with a strong preference for ssRNA over ssDNA, identifying its biochemical substrate.\",\n      \"evidence\": \"In vitro exonuclease assays with purified protein, metal and pH optimization\",\n      \"pmids\": [\"11401564\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No cellular substrate identified\", \"No structural basis for RNA preference\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Connected the enzymatic activity to a biological role by showing exonuclease-dependent restriction of RNA but not DNA viruses, establishing ISG20 as an antiviral effector.\",\n      \"evidence\": \"Overexpression of WT and active-site-dead ISG20 in HeLa cells with VSV/influenza/EMCV/adenovirus infection\",\n      \"pmids\": [\"12594219\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not show direct degradation of viral RNA in cells\", \"Mechanism of viral RNA selectivity unknown\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Resolved the structural basis of RNA substrate preference, placing ISG20 in the DEDDh family and identifying ribose-contacting residues.\",\n      \"evidence\": \"X-ray crystallography at 1.9 \\u00c5 with Mn2+ and UMP plus comparison to DNase homologs\",\n      \"pmids\": [\"15527770\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No structure with a longer RNA or viral substrate\", \"Did not address how modifications affect catalysis\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"Showed a second induction pathway via dsRNA-driven NF-\\u03baB then IRF-1, with distinct subcellular consequences, broadening the contexts that mobilize ISG20.\",\n      \"evidence\": \"Reporter assays, EMSA and fractionation comparing poly I:C versus IFN induction\",\n      \"pmids\": [\"15064705\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single lab\", \"Functional consequence of nuclear matrix enrichment not defined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Mapped endogenous ISG20 to nucleolar and Cajal body compartments and to snRNP/snoRNA machinery, hinting at a role beyond viral defense.\",\n      \"evidence\": \"Immunofluorescence, EM, SMN co-IP and RNA-IP for U snRNAs/U3 snoRNA\",\n      \"pmids\": [\"16514659\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of snRNA association not tested\", \"Did not establish whether localization is required for antiviral activity\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Extended exonuclease-dependent restriction to multiple positive-strand RNA viruses in a cell-type-specific manner and established paralog specificity.\",\n      \"evidence\": \"Ectopic expression with active-site mutant across HCV, BVDV, HAV, YFV, SARS-CoV and ISG20L1/L2 controls\",\n      \"pmids\": [\"21036379\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Basis of cell-type specificity unknown\", \"No direct viral RNA degradation demonstrated\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified influenza nucleoprotein as a viral interaction partner and linked ISG20 to impaired viral polymerase function.\",\n      \"evidence\": \"Co-IP and co-localization of ISG20 with IAV NP, polymerase activity assays, active-site mutant\",\n      \"pmids\": [\"27342813\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Single Co-IP context; NP interaction inferred to depend on activity\", \"Direct vs indirect effect on polymerase not separated\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Provided the clearest case of direct, structure-guided substrate recognition by mapping ISG20 binding to the HBV epsilon stem-loop via its ExoIII domain and revealing a degradation-independent restriction mode.\",\n      \"evidence\": \"EMSA direct binding, ExoIII deletion, epsilon structure mutants, catalytic-dead ISG20D94G encapsidation assays\",\n      \"pmids\": [\"28399146\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Generality of stem-loop recognition to other viruses untested\", \"No co-structure of ISG20 bound to epsilon\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Revealed an indirect antiviral mechanism for alphaviruses in which ISG20 amplifies ISGs like IFIT1 rather than degrading viral RNA, diversifying its mode of action.\",\n      \"evidence\": \"Inducible expression, RNA-seq, negative viral RNA degradation assay, Isg20-/- mice\",\n      \"pmids\": [\"30232164\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which ISG20 upregulates ISGs unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Confirmed RNase-dependent antibunyaviral activity through a functional ISG screen and mapped viral sequence determinants of sensitivity.\",\n      \"evidence\": \"ISG-expression flow cytometry screen, minigenome/VLP assays, active-site mutant, in vitro viral evolution\",\n      \"pmids\": [\"29695422\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Why phleboviruses escape unresolved\", \"Direct degradation of bunyaviral RNA not shown\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Defined a translational-inhibition mechanism distinct from degradation, localized to P-bodies and based on self/non-self RNA discrimination, with KO mice confirming physiological relevance.\",\n      \"evidence\": \"Ribosome/translation assays, negative RNA stability assays, P-body live imaging, Isg20-/- mice, murine ortholog\",\n      \"pmids\": [\"31600344\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of self/non-self discrimination at P-bodies incomplete\", \"Relationship between translational control and exonuclease activity not fully resolved\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identified the m6A-YTHDF2 axis as a cofactor system directing ISG20 to m6A-modified HBV RNA, linking epitranscriptomics to substrate selection.\",\n      \"evidence\": \"Catalytic-dead ISG20D94G co-IP of YTHDF2 and m6A RNA, methyltransferase/YTHDF2 knockdowns, HBV m6A site mutants, decay assays\",\n      \"pmids\": [\"32059034\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether YTHDF2 directs ISG20 to non-HBV substrates not addressed\", \"Structural basis of the ternary complex unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Implicated ISG20 in nuclear RNA quality control of spliceosomal U snRNA precursors alongside the nuclear exosome, supporting a housekeeping function.\",\n      \"evidence\": \"In vitro 3'-end maturation assay, ISG20 and exosome knockdown, U1 snRNA 3'-end sequencing\",\n      \"pmids\": [\"33147372\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative contribution of ISG20 vs exosome unclear\", \"Link to antiviral role not established\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Extended ISG20 activity to deaminated HBV cccDNA, identifying it as the nuclease mediating IFN-induced cccDNA loss in cooperation with APOBEC3A.\",\n      \"evidence\": \"ISG20 depletion/co-expression, nucleolar localization, deoxyuridine-ssDNA enrichment, cccDNA quantification\",\n      \"pmids\": [\"33969602\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct nuclease action on cccDNA versus indirect effects not fully separated\", \"Single lab\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established that 2'O-methylation blocks ISG20 by steric clash at R53/D90, explaining how host RNA marks and viral RNA modification status govern degradation susceptibility.\",\n      \"evidence\": \"In vitro degradation of 2'O-methylated substrates, R53/D90 mutagenesis, FTSJ3-KO hypomethylated HIV-1, T-cell infection\",\n      \"pmids\": [\"36354007\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo contribution of 2'O-methylation evasion to viral fitness untested\", \"Interplay with m6A-directed degradation not integrated\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Revealed a pro-tumor function in which ISG20 degrades specific cellular mRNAs (RHOBTB3, STAT1, IRF1) to remodel the immune microenvironment, extending its substrate repertoire to host transcripts.\",\n      \"evidence\": \"ISG20 KD/OE in TNBC, mRNA decay assays, HIF-1\\u03b1/NANOG/CXCL10 readouts, anti-PD1 mouse model\",\n      \"pmids\": [\"41385111\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Selectivity rules for these mRNAs versus protected transcripts unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined how cellular mRNAs evade ISG20, showing PABP1 poly(A) loading and stable 3' stem-loops provide protection, completing the self/non-self discrimination model.\",\n      \"evidence\": \"RNA-seq, biochemical PABP1 loading assays, stem-loop stability analysis, histone mRNA quantification\",\n      \"pmids\": [\"38418089\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How viral RNAs avoid equivalent protection not fully resolved\", \"Single lab\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Showed that m6A can also antagonize ISG20 via YTHDF1 on the EBOV genome, demonstrating that the same mark can promote or block degradation depending on the reader.\",\n      \"evidence\": \"EBOV m6A mapping, ISG20/YTHDF1 knockdown, m6A site mutants, co-IP, replication assays\",\n      \"pmids\": [\"41423124\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism distinguishing YTHDF1 antagonism from YTHDF2 promotion unclear\", \"Single lab\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Demonstrated indirect restriction of DNA herpesviruses through IFN signaling amplification, confirmed by JAK-STAT inhibition rescue, reinforcing the non-degradative arm of ISG20 action.\",\n      \"evidence\": \"OE/KD, RNA-seq, negative viral RNA/DNA half-life assays, ruxolitinib rescue, scRNA-seq\",\n      \"pmids\": [\"41511982\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular trigger by which ISG20 amplifies IFN unknown\", \"Single lab\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ISG20 integrates its multiple modes (direct degradation, translational inhibition, ISG amplification) and what determines which mode operates for a given target remains unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model linking substrate features, localization and mechanism choice\", \"No structure of ISG20 engaging a modified or structured viral RNA\", \"Mechanism by which catalytic-independent ISG amplification occurs unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140098\", \"supporting_discovery_ids\": [0, 3, 8, 15]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [0, 1]},\n      {\"term_id\": \"GO:0003723\", \"supporting_discovery_ids\": [0, 8]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005730\", \"supporting_discovery_ids\": [6, 13]},\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 9]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [6, 11]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 3, 9, 20]},\n      {\"term_id\": \"R-HSA-8953854\", \"supporting_discovery_ids\": [11, 14, 18]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [5, 8, 17]}\n    ],\n    \"complexes\": [\"SMN complex\"],\n    \"partners\": [\"YTHDF2\", \"YTHDF1\", \"PABP1\", \"IAV NP\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win"}}